Skyrizi® COMPLETE

CONTACT DETAILS FOR **SPECIALTY PHARMACIES**

INDICATIONS[1]

Plaque Psoriasis: SKYRIZI is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Psoriatic Arthritis: SKYRIZI is indicated for the treatment of active psoriatic arthritis in adults.

Crohn's Disease: SKYRIZI is indicated for the treatment of moderately to severely active Crohn's disease in adults.

Ulcerative Colitis: SKYRIZI is indicated for the treatment of moderately to severely active ulcerative colitis in adults.

SAFETY CONSIDERATIONS[1]

SKYRIZI is contraindicated in patients with a history of serious hypersensitivity reaction to risankizumab-rzaa or any of its excipients. Serious hypersensitivity reactions, including anaphylaxis, have been reported with use of SKYRIZI. If a serious hypersensitivity reaction occurs, discontinue SKYRIZI and initiate appropriate therapy immediately. SKYRIZI may increase the risk of infection. Instruct patients to report signs or symptoms of clinically important infection during treatment. Should such an infection occur, discontinue SKYRIZI until infection resolves. Evaluate patients for tuberculosis infection prior to initiating treatment with SKYRIZI. Drug-induced liver injury was reported in a patient with Crohn's disease during induction dosing of SKYRIZI. For the treatment of Crohn's disease and ulcerative colitis, evaluate liver enzymes and bilirubin at baseline and during induction (12 weeks). Interrupt treatment with SKYRIZI if drug-induced liver injury is suspected, until this diagnosis is excluded. Avoid use of live vaccines in SKYRIZI patients.

Please see Indications and Important Safety Information on page 3.

Please click here for full Prescribing Information.

Skyrizi®
risankizumab-rzaa

CONTACT DETAILS FOR **SPECIALTY PHARMACIES**

Specialty Pharmacies are designed to:

- Dispense medications, including those with complex access and/or handling requirements
- Provide educational support to patients for medications that may not normally be available through retail pharmacies

Specialty Pharmacy contact details

All Specialty Pharmacies can dispense and ship SKYRIZI. Abbvie's Specialty Pharmacy Service Network (SPSN) can provide additional product-specific support.

AcariaHealth	T: 800.511.5144	F: 877.541.1503	acariahealth.com
Accredo	T: 800.803.2523	F: 888.302.1028	accredo.com
Ardon Health	T: 855.425.4085	F: 855.425.4096	ardonhealth.com
BioPlus Specialty Pharmacy	T: 888.292.0744	F: 800.269.5493	bioplusrx.com
Blue Sky Specialty Pharmacy	T: 866.822.0103	F: 833.898.3992	blueskyspecialtypharmacy.com
CenterWell Specialty Pharmacy	T: 800.486.2668	F: 877.405.7940	centerwellpharmacy.com
CVS Specialty	T: 800.237.2767	F: 800.323.2445	cvsspecialty.com
Kroger Specialty Pharmacy	T: 888.355.4191	F: 888.355.4192	krogerspecialtypharmacy.com
Lumicera Health Services	T: 855.847.3553	F: 855.847.3558	lumicera.com
Magellan Rx	T: 866.554.2673	F: 866.364.2673	magellanhealth.com
Meijer Specialty Pharmacy	T: 855.263.4537	F: 877.222.5036	meijerspecialtypharmacy.com
Noble Health Services	T: 888.843.2040	F: 888.842.3977	noblehealthservices.com
Optum Specialty Pharmacy	T: 855.427.4682	F: 877.342.4596	specialty.optumrx.com
Senderra Specialty Pharmacy	T: 888.777.5547	F: 888.777.5645	senderrarx.com
Walgreens Specialty Pharmacy	T: 800.345.1985	F: 877.231.8302	alliancerxwp.com
Walmart	T: 877.453.4566	F: 866.537.0877	walmart.com/specialtypharmacy

SKYRIZI is broadly available via open distribution, and prescriptions may be sent to the Specialty Pharmacy of the patient's choosing.

For support in person or over the phone, call an Access Specialist at 1.877.COMPLETE (1.877.266.7538)

Please see Indications and Important Safety Information on page 3.

Please click here for full Prescribing Information.

Skyrizi® COMPLETE

Skyrizi®
risankizumab-rzaa

INDICATIONS AND IMPORTANT SAFETY INFORMATION FOR SKYRIZI® (risankizumab-rzaa)

INDICATIONS[1]

Plaque Psoriasis: SKYRIZI is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Psoriatic Arthritis: SKYRIZI is indicated for the treatment of active psoriatic arthritis in adults.

Crohn's Disease: SKYRIZI is indicated for the treatment of moderately to severely active Crohn's disease in adults.

Ulcerative Colitis: SKYRIZI is indicated for the treatment of moderately to severely active ulcerative colitis in adults.

IMPORTANT SAFETY INFORMATION[1]

Hypersensitivity Reactions

SKYRIZI® (risankizumab-rzaa) is contraindicated in patients with a history of serious hypersensitivity reaction to risankizumab-rzaa or any of the excipients. Serious hypersensitivity reactions, including anaphylaxis, have been reported with the use of SKYRIZI. If a serious hypersensitivity reaction occurs, discontinue SKYRIZI and initiate appropriate therapy immediately.

Infection

SKYRIZI may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves or is adequately treated.

In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing SKYRIZI. Instruct patients to seek medical advice if signs or symptoms of clinically important infection occur. If a patient develops such an infection or is not responding to standard therapy, closely monitor and discontinue SKYRIZI until the infection resolves.

Tuberculosis (TB)

Prior to initiating treatment with SKYRIZI, evaluate for TB infection and consider treatment in patients with latent or active TB for whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after SKYRIZI treatment. Do not administer SKYRIZI to patients with active TB.

Hepatotoxicity in Treatment of Inflammatory Bowel Disease

Drug-induced liver injury was reported in a patient with Crohn's disease who was hospitalized for a rash during induction dosing of SKYRIZI. For the treatment of Crohn's disease and ulcerative colitis, evaluate liver enzymes and bilirubin at baseline and during induction (12 weeks); monitor thereafter according to routine patient management. Consider an alternate treatment for patients with evidence of liver cirrhosis. Interrupt treatment if drug-induced liver injury is suspected, until this diagnosis is excluded. Instruct your patient to seek immediate medical attention if they experience symptoms suggestive of hepatic dysfunction.

Administration of Vaccines

Avoid use of live vaccines in patients treated with SKYRIZI. Medications that interact with the immune system may increase the risk of infection following administration of live vaccines. Prior to initiating SKYRIZI, complete all age-appropriate vaccinations according to current immunization guidelines.

Adverse Reactions

Most common (≥1%) adverse reactions associated with SKYRIZI in plaque psoriasis and psoriatic arthritis include upper respiratory infections, headache, fatigue, injection site reactions, and tinea infections.

In psoriatic arthritis phase 3 trials, the incidence of hepatic events was higher with SKYRIZI compared to placebo.

Most common (>3%) adverse reactions associated with SKYRIZI in Crohn's disease are upper respiratory infections, headache, and arthralgia in induction, and arthralgia, abdominal pain, injection site reactions, anemia, pyrexia, back pain, arthropathy, and urinary tract infection in maintenance.

Most common (≥3%) adverse reactions associated with SKYRIZI in ulcerative colitis are arthralgia in induction, and arthralgia, pyrexia, injection site reactions, and rash in maintenance.

Lipid Elevations: Increases from baseline and increases relative to placebo were observed at Week 4 and remained stable to Week 12 in patients treated with SKYRIZI in Crohn's disease. Lipid elevations observed in patients with ulcerative colitis were similar to those in Crohn's disease.

Dosage Forms and Strengths: SKYRIZI (risankizumab-rzaa) is available in a 150 mg/mL prefilled syringe and pen, a 600 mg/10 mL single-dose vial for intravenous infusion, and a 180 mg/1.2 mL or 360 mg/2.4 mL single-dose prefilled cartridge with on-body injector.

Please click here for full Prescribing Information.

Reference: 1. SKYRIZI [package insert]. North Chicago, IL: AbbVie Inc.

abbvie

US-SKZ-240167 June 2024

Skyrizi® risankizumab-rzaa